Financial Performance - The company's operating revenue for the first half of 2024 was ¥898,125,095.81, representing a decrease of 9.97% compared to ¥997,633,605.73 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was ¥35,809,610.69, down 44.93% from ¥65,023,439.88 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was ¥14,681,515.49, a decline of 62.89% compared to ¥39,564,893.56 in the same period last year[11]. - Basic earnings per share decreased to ¥0.0897, down 47.51% from ¥0.1709 in the same period last year[11]. - The gross profit margin for the pharmaceutical manufacturing sector decreased by 5.44% to 23.24%[29]. - The total profit for the first half of 2024 was CNY 41,419,361.74, significantly lower than CNY 76,092,913.33 in the same period of 2023, marking a decline of about 45.5%[109]. - Operating profit for the first half of 2024 was CNY 41,760,234.39, down from CNY 77,596,668.64, reflecting a decline of about 46.3%[108]. Cash Flow and Investments - The net cash flow from operating activities improved to -¥18,462,390.04, an 83.26% increase from -¥110,283,913.04 in the previous year[11]. - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥271,285,818.47, a 724.49% improvement compared to the previous year[28]. - The company's cash flow from investment activities increased by 119.42% to ¥419,641,649.48, mainly due to cash recovered from investments[28]. - The company reported a net cash flow from investment activities of 419,641,649.48 CNY, a substantial recovery from -2,161,276,792.83 CNY in the first half of 2023[115]. - The company reported cash inflow from investment recovery of 2,483,000,000.00 CNY, with no comparable figure from the previous year[113]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,844,315,787.46, an increase of 3.43% from ¥5,650,770,791.34 at the end of the previous year[11]. - The company's inventory increased to ¥234,191,630.23, representing 4.01% of total assets, up from 3.39% the previous year[31]. - The total liabilities increased to CNY 1,497,988,606.82 from CNY 1,290,933,355.79, an increase of 16.14%[106]. - The company's total non-current assets amounted to ¥2,796,732,514.97, compared to ¥2,448,505,159.56, marking an increase of about 14.2%[102]. Research and Development - The company's R&D investment increased by 15.89% to ¥30,793,313.49, indicating a focus on innovation and product development[28]. - The company is committed to continuous innovation and technology upgrades to improve its competitive edge in both the pharmaceutical and lithium battery sectors[19]. Market Position and Strategy - The company has established a complete pharmaceutical supply chain, becoming a major supplier of nitroimidazole antibiotics and acyclovir raw materials, with core products like metronidazole holding a leading market share[16]. - In the lithium battery sector, the company is one of the earliest producers of lithium hexafluorophosphate, with a domestic market share of 73.8% in lithium-ion battery shipments, which totaled 887.4 GWh in 2023, a 34.3% year-on-year increase[18][19]. - The company plans to expand its pharmaceutical product pipeline and enhance its market competitiveness by focusing on high-end raw materials and generic drug approvals in the domestic market[19]. Risk Management - The company faced various operational risks, which are detailed in the risk management section of the report[2]. - The company faces risks from fluctuations in raw material prices, which can impact gross margins if sales prices do not adjust timely to rising costs[49]. - The company is increasing R&D efforts to enhance product value and improve sales systems to mitigate risks from potential price declines in its products[50]. Environmental and Social Responsibility - The company reported a total capitalized investment of CNY 5,058,434.59 and an expense investment of CNY 17,614,912.46, totaling CNY 22,673,347.05 for environmental protection in the first half of 2024[63]. - The company has implemented a self-monitoring plan for pollutants, ensuring 100% reporting of monitoring data[62]. - The company has participated in social responsibility activities, providing employment and supporting disadvantaged groups[69]. Shareholder Information - The company held its first extraordinary shareholders' meeting on April 1, 2024, with a participation rate of 62.24%[56]. - The company did not distribute cash dividends or issue bonus shares for the first half of 2024[57]. - The total number of shareholders at the end of the reporting period was 34,781, with 5% or more shareholders holding significant stakes[94]. Accounting Policies - The financial statements comply with the requirements of the accounting standards and reflect the financial position as of June 30, 2024, and the operating results for the first half of 2024[135]. - The company has established specific accounting policies and estimates based on its production and operational characteristics, particularly regarding revenue recognition[134]. - The company recognizes revenue when control of goods is transferred to customers, which includes conditions such as approval of the contract and the ability to collect payment[196].

证券代码：301246 证券简称：宏源药业 公告编号：2024-037 湖北省宏源药业科技股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖北省宏源药业科技股份有限公司（以下简称"公司"）第四届董事会第七 次会议于 2024 年 8 月 28 日在公司会议室以现场会议与通讯相结合方式召开。会 议通知及材料于 2024 年 8 月 17 日以通讯的形式送达公司各位董事、监事及高级 管理人员。本次会议由董事长尹国平先生主持，公司应出席董事 9 名，实际出席 董事 9 名，其中董事阎晓辉先生、陈家春先生、卢世刚先生、周楷唐先生以通讯 方式出席。公司监事、高级管理人员列席了会议。本次董事会会议的召开符合《公 司法》和章程的有关规定，所做决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于<2024 年半年度报告>及其摘要的议案》 董事会认为公司《2024 年半年度报告》及《2024 年半年度报告摘要》符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 经营的实际情况 ...

| 非经营性资金占 | | 占用方与上市公司 | 上市公司核算 | 2024年初占用资 | 2024年1-6月 占用累计发生 | 2024年1-6月 占用资金的 | 2024年1-6月偿 | 2024年6月30日 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 用 | 资金占用方名称 | 的关联关系 | 的会计科目 | 金余额 | 金额（不含利 | 利息（如 | 还累计发生额 | 占用资金余额 | 原因 | | | | | | | | 息） | 有） | | | | | | 控股股东、实际 | | | | | | | | | | | | 控制人及其附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 前控股股东、实 | | | | | | | | | | | | 际控制人及其附 | | | | | | | | | | | | 属企业 | | | | ...

证券代码：301246 证券简称：宏源药业 公告编号：2024-038 湖北省宏源药业科技股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 湖北省宏源药业科技股份有限公司（以下简称"公司"）第四届监事会第六 次会议于 2024 年 8 月 28 日以现场方式在公司会议室召开。会议通知及材料于 2024 年 8 月 17 日以通讯的形式送达公司各位监事。本次会议应出席监事 5 人， 实际出席监事 5 人。本次监事会会议的召开符合《公司法》和《公司章程》的有 关规定，所做决议合法有效。 1、审议通过了《关于<2024 年半年度报告>及其摘要的议案》 经审议，监事会认为：董事会编制和审议公司《2024 年半年度报告》及《2024 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容 能够真实、准确、完整地反映公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2024 年半年度报告》及《202 ...

证券代码：301246 证券简称：宏源药业 公告编号：2024-036 湖北省宏源药业科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2024 年 3 月 13 日召开第四届董事会第五次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用不超过人民币 9,920.00 万元（含）的自有资金以集中竞价交易方 式回购公司股份，回购股份的价格不超过 31 元/股（未超过公司董事会审议通过 回购股份方案前三十个交易日公司股票交易均价的 150%），预计回购股份数量 回购公司股份 3,200,000 股（含）—1,600,000 股（含），占公司总股本的比例 为 0.80%—0.40%，具体回购股份的数量以回购实施完毕或实施期限届满时实际 回购的股份数量为准。本次回购股份的实施期限为自董事会审议通过回购股份方 案之日起 12 个月内。本次回购股份将用于股权激励或员工持股计划。具体内 容详见公司于 2024 年 3 月 15 日、2024 年 3 月 21 日在巨潮 ...

证券代码：301246 证券简称：宏源药业 公告编号：2024-034 湖北省宏源药业科技股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《中华人民共和国公司法》（以下简称"公司法"）、《深圳证券 交易所上市公司自律监管指引第 9 号—回购股份》等相关规定，湖北省宏源药业 科技股份有限公司(以下简称"公司"或"本公司"）回购专用证券账户中的股 份 2,000,000 股不参与本次权益分派。本次权益分派将以公司现有总股本 400,006,800 股剔除回购专用证券账户中的股份 2,000,000 股后的股本 398,006,800 股为基数，向全体股东每 10 股派 0.50 元人民币现金（含税），实 际派发现金分红总额=398,006,800股×0.50元/10股=19,900,340.00元人民币。 2、本次权益分派实施后计算除权除息价格时，按公司总股本（含回购股份） 折算的每 10 股现金分红=现金分红总额÷总股本（含回购股份）×10 股 =19,900,340.00 元÷400,006, ...

一、回购公司股份进展情况 截至 2024 年 6 月 30 日，公司通过回购专用证券账户以集中竞价交易方式累 计回购公司股份 2,000,000 股，占公司目前总股本的 0.50%，最高成交价为 17.92 元/股，最低成交价为 13.19 元/股，成交总金额为人民币 31,153,738 元（不含 证券代码：301246 证券简称：宏源药业 公告编号：2024-035 湖北省宏源药业科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2024 年 3 月 13 日召开第四届董事会第五次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用不超过人民币 9,920.00 万元（含）的自有资金以集中竞价交易方 式回购公司股份，回购股份的价格不超过 31 元/股（未超过公司董事会审议通过 回购股份方案前三十个交易日公司股票交易均价的 150%），预计回购股份数量 回购公司股份 3,200,000 股（含）—1,600,000 股（含），占公司总股本的比例 为 0. ...

证券代码：301246 证券简称：宏源药业 公告编号：2024-033 湖北省宏源药业科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2024 年 3 月 13 日召开第四届董事会第五次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用不超过人民币 9,920.00 万元（含）的自有资金以集中竞价交易方 式回购公司股份，回购股份的价格不超过 31 元/股（未超过公司董事会审议通过 回购股份方案前三十个交易日公司股票交易均价的 150%），预计回购股份数量 回购公司股份 3,200,000 股（含）—1,600,000 股（含），占公司总股本的比例 为 0.80%—0.40%，具体回购股份的数量以回购实施完毕或实施期限届满时实际 回购的股份数量为准。如公司在回购期内发生资本公积转增股本、派发股票或现 金红利等除权除息事项，自股价除权除息之日起，按照中国证监会及深圳证券交 易所的相关规定相应调整回购股份价格上限，回购股份数量和占公司总股本比例 相应变化。本 ...

Group 1: R&D and Innovation - The company emphasizes "innovation and development" as its core values, continuously increasing R&D investment to enhance product technology levels and maintain competitiveness [2][6]. - In 2023, the company significantly increased R&D spending, indicating active development of new product lines and technology upgrades [2][3]. - The company aims to develop new advantageous processes around existing products to ensure long-term competitiveness [4][6]. Group 2: Financial Performance and Investments - In 2023, the company's investment income saw a significant increase, particularly from joint ventures and associates [3]. - The company reported a decrease in inventory impairment losses by 32.63%, amounting to 26.38 million yuan [5]. - The company’s investment properties account for only 0.07% of total assets, contributing minimally to overall performance [4]. Group 3: Market Position and Competitive Advantage - The company has established a comprehensive pharmaceutical supply chain, becoming a leading supplier in the nitroimidazole antibiotic and antiviral drug markets [4]. - It holds the largest market share in the nitroimidazole antibiotic segment, recognized for product quality and cost competitiveness [4]. - The company plans to expand its product line and enhance its international market presence while promoting generic drug approvals domestically [4][7]. Group 4: Operational Efficiency and Risk Management - The company has implemented strict management of prepayments, ensuring minimal overdue amounts and safeguarding funds [5]. - It actively monitors raw material price fluctuations and adjusts production plans accordingly to control costs [7]. - The company maintains a robust internal control system, regularly updating it to address risk management and compliance [6][8]. Group 5: Future Strategies and Development Plans - The company is focusing on the lithium battery materials sector, planning to enhance competitiveness through product diversification and technological upgrades [6][8]. - It is also exploring the development of solid-state battery electrolytes to capture market opportunities in clean energy [8]. - The company aims to continuously enrich its pharmaceutical product pipeline to achieve balanced and stable profit growth [7].

证券代码：301246 证券简称：宏源药业 公告编号：2024-031 湖北省宏源药业科技股份有限公司 关于参加湖北辖区上市公司 2024 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，湖北省宏源药业科技股份有限公司（以下 简称“公司”）将参加由湖北证监局指导、湖北省上市公司协会主办、深圳市全景网 络有限公司承办的“提质增效重回报”——2024 年湖北辖区上市公司投资者网上集 体接待日，现将相关事项公告如下： （一）本次活动将采用网络远程的方式举行，投资者可登录“全景路演”网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP 参与本次 互动交流，活动时间为 2024年5月 16日（星期四）14:30-16:00。届时公司副董事长 尹聃先生，财务负责人曾科峰先生，总监、董事会秘书肖拥华先生将在线就公司 2023 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续发展等投 资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ ...